Replies to post #16 on Bottom Swing Plays Chat

[gdog]

Well I'm thinking this news should give it the boost for 10-20% gain. Hopefully for us it does.


Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved

- On Track to Regain Compliance with All Nasdaq Listing Requirements

- No Variable Priced Securities are Outstanding

[gdog]

ALLR starting to creep back up. hod .7185

[gdog]

Item 2.02 Results of Operations and Financial Condition.



On May 14, 2024, the Company issued a press release announcing its financial results for its fiscal quarter ended March 31, 2024 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.



Item 8.01 Other Events.



The Press Release discussed that the Company concluded its Phase 2 clinical trial of stenoparib early due to clear clinical benefits observed, including tumor shrinkage and long-term disease stability, in heavily pre-treated ovarian cancer patients. Using the Company’s DRP® companion diagnostic to pre-screen patients, the trial targeted those most likely to benefit. The promising results have provided sufficient proof of concept, prompting the Company to halt enrollment with the purpose of preparing a follow-on trial with FDA regulatory intent.